TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
Go back to TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 213.58 -7.25 (3.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $220.83 | 52 Week High | $333.65 | |||
| Open | $215.45 | 52 Week Low | $223.02 | |||
| Day High | $217.28 | P/E | 27.35 | |||
| Day Low | $210.54 | EPS | $7.81 | |||
| Volume | 119,088 | |||||

